申请人:Sato Seiichi
公开号:US20060189621A1
公开(公告)日:2006-08-24
The present invention is directed to a compound represented by formula (1):
(wherein R
1
represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and
each of R
2
and R
3
represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R
2
and R
3
form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-α) production inhibitory effect and improved absorption upon oral administration.
本发明涉及一种由式(1)表示的化合物:(其中R1表示可以具有取代基的烷基或可以具有取代基的烯基基团;R2和R3中的每一个表示氢原子、烷基、羟基烷基、二羟基烷基或炔基,或者R2和R3与其相邻的氮原子一起形成可以具有取代基的含氮饱和杂环基团),以及含有该化合物的药物组合物。该化合物表现出肿瘤坏死因子(TNF-α)生产抑制作用和口服吸收改善。